| Literature DB >> 28686006 |
Nazia Raja-Khan1, Katrina Agito1, Julie Shah1, Christy M Stetter2, Theresa S Gustafson3, Holly Socolow1, Allen R Kunselman2, Diane K Reibel4, Richard S Legro5.
Abstract
OBJECTIVE: To evaluate the feasibility and cardiometabolic effects of mindfulness-based stress reduction (MBSR) in women with overweight or obesity.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28686006 PMCID: PMC5529243 DOI: 10.1002/oby.21910
Source DB: PubMed Journal: Obesity (Silver Spring) ISSN: 1930-7381 Impact factor: 5.002
Baseline characteristics of randomized participants
|
Total |
Mindfulness‐based stress reduction |
Health education | |
|---|---|---|---|
|
| 44.5 (12.5) | 47.0 (11.5) | 42.2 (13.1) |
|
| |||
|
| 77 (89.5) | 37 (88.1) | 40 (90.9) |
|
| 5 (5.8) | 3 (7.1) | 2 (4.6) |
|
| 4 (4.7) | 2 (4.8) | 2 (4.6) |
|
| 4 (4.7) | 1 (2.4) | 3 (6.8) |
|
| 103.2 (24.1) | 104.2 (21.5) | 102.3 (26.6) |
|
| 38.9 (8.7) | 39.0 (7.7) | 38.8 (9.7) |
|
| 111.3 (19.0) | 112.6 (20.3) | 110.0 (17.8) |
|
| 124.3 (16.2) | 126.2 (16.7) | 122.4 (15.7) |
|
| 77.7 (8.5) | 79.2 (8.6) | 76.2 (8.3) |
|
| 35 (40.7) | 17 (40.5) | 18 (40.9) |
|
| 21 (24.4) | 10 (23.8) | 11 (25.0) |
|
| 32 (37.2) | 15 (35.7) | 17 (38.6) |
|
| |||
|
| 105.1 (46.0) | 101.7 (45.0) | 108.2 (47.3) |
|
| 31.3 (28.3) | 30.3 (22.0) | 32.4 (33.6) |
|
| 3.9 (3.2) | 3.7 (2.7) | 4.0 (3.7) |
|
|
6.3 (1.6) |
6.2 (1.4) |
6.4 (1.7) |
|
| 191.5 (36.5) | 190.8 (41.9) | 192.2 (30.9) |
|
| 41.6 (15.0) | 41.7 (14.7) | 41.4 (15.3) |
|
| 117.4 (32.9) | 118.7 (39.9) | 116.1 (24.5) |
|
| 181.1 (187.3) | 159.7 (83.4) | 201.5 (248.7) |
|
| 10.2 (9.7) | 9.7 (9.9) | 10.7 (9.6) |
|
| |||
|
| 22.6 (11.1) | 24.3 (10.1) | 20.9 (11.8) |
|
| 11.8 (5.6) | 12.7 (5.5) | 10.9 (5.6) |
|
| 10.8 (6.5) | 11.6 (5.8) | 10.0 (7.0) |
|
| 22.2 (3.0) | 22.8 (3.2) | 21.6 (2.8) |
|
| 55.9 (9.2) | 55.9 (9.3) | 56.0 (9.2) |
|
| |||
|
| 41.5 (11.6) | 40.5 (11.7) | 42.4 (11.5) |
|
| 46.3 (11.6) | 45.9 (12.2) | 46.6 (11.2) |
|
| 55.3 (10.1) | 55.4 (9.7) | 55.3 (10.6) |
|
| 54.4 (9.8) | 54.5 (10.3) | 54.4 (9.3) |
|
| 53.5 (10.0) | 54.0 (9.9) | 53.0 (10.2) |
|
| 55.6 (11.0) | 55.6 (10.6) | 55.6 (11.5) |
|
| 28.3 (8.8) | 28.2 (9.0) | 28.3 (8.6) |
|
| 21.1 (7.7) | 22.3 (7.9) | 19.8 (7.3) |
Data are expressed as mean (SD) unless otherwise noted.
Range of possible scores for TMS: 0 to 28 for TMS Decentering subscore; 0 to 24 for TMS Curiosity subscore; 0 to 52 for TMS total score, which is the arithmetic sum of the two subscores. Higher values indicate a greater ability to be mindful, a state of curious, decentered awareness.
Range of possible scores for Perceived Stress Scale‐10: 0 to 40. Higher values indicate greater perceived stress.
T‐scores and SF‐36 summary scales rescale the raw score into a standardized score with a mean of 50 and a SD of 10. For example, a T‐score of 60 is 1 SD greater than the mean for the general population.
Range of possible scores for each of the PANAS scores: 10 to 50. Higher Positive Affect scores indicate greater positive affect. Higher Negative Affect scores indicate greater negative affect.
Abbreviations: BSI‐18, Brief Symptom Inventory‐18; HOMA‐IR, homeostatic index of insulin resistance; HsCRP, high sensitive C‐reactive protein; LDL, low‐density lipoprotein; HDL, high‐density lipoprotein; PANAS, Positive and Negative Affect Schedule; PROMIS, Patient‐Reported Outcomes Measurement Information System; SF‐36, Short Form‐36; TMS, Toronto Mindfulness Scale.
Figure 1CONSORT flow diagram showing the progress of participants through each stage of this randomized clinical trial.
Changes from baseline in mindfulness, quality of life, and psychological measures (intent‐to‐treat analysis)
|
Mindfulness‐based stress reduction |
Health education |
Mindfulness‐based stress reduction | ||||
|---|---|---|---|---|---|---|
|
8‐week |
16‐week |
8‐week |
16‐week |
8‐week |
16‐week | |
|
| ||||||
|
| 4.5 (1.2 to 7.7) | 2.2 (−2.2 to 6.7) | −1.0 (−4.4 to 2.5) | −2.0 (−7.0 to 2.9) | 5.4 (0.7 to 10.2) | 4.2 (−2.4 to 10.9) |
|
| 3.0 (1.1 to 4.9) | 1.5 (−0.9 to 3.8) | −0.6 (−2.7 to 1.4) | −1.1 (−3.8 to 1.5) | 3.6 (0.9 to 6.4) | 2.6 (−0.9 to 6.1) |
|
| 1.4 (−0.5 to 3.3) | 0.7 (−1.7 to 3.2) | −0.4 (−2.5 to 1.6) | −0.8 (−3.5 to 1.8) | 1.8 (−1.0 to 4.6) | 1.6 (−2.1 to 5.2) |
|
| ||||||
|
| −2.2 (−3.3 to −1.2) | −3.6 (−4.7 to −2.5) | −1.3 (−2.5 to −0.2) | −1.3 (−2.6 to −0.0) | −0.9 (−2.5 to 0.7) | −2.3 (−4.0 to −0.6) |
|
| −5.7 (−8.0 to −3.3) | −4.3 (−7.1 to −1.5) | −7.8 (−10.3 to −5.2) | −7.8 (−11.0 to −4.6) | 2.1 (−1.3 to 5.6) | 3.5 (−0.8 to 7.7) |
|
| 8.0 (4.9 to 11.1) | 5.3 (1.8 to 8.8) | 4.1 (0.6 to 7.6) | 3.3 (−0.7 to 7.2) | 3.9 (−0.8 to 8.5) | 2.1 (−3.2 to 7.3) |
|
| −0.2 (−2.2 to 1.8) | 1.6 (−0.8 to 4.1) | −0.4 (−2.7 to 1.9) | 2.8 (0.1 to 5.5) | 0.2 (−2.8 to 3.3) | −1.2 (−4.8 to 2.5) |
|
| −3.2 (−5.4 to −0.9) | −2.8 (−5.5 to −0.2) | −4.4 (−6.9 to −1.9) | −3.7 (−6.7 to −0.6) | 1.2 (−2.2 to 4.6) | 0.8 (−3.2 to 4.9) |
|
| −3.8 (−6.6 to −1.0) | −2.9 (−6.0 to 0.3) | −2.7 (−5.7 to 0.4) | −2.6 (−6.2 to 0.9) | −1.1 (−5.3 to 3.0) | −0.2 (−5.0 to 4.5) |
|
| −4.0 (−6.7 to −1.3) | −4.2 (−7.1 to −1.3) | −3.6 (−6.6 to −0.7) | −3.0 (−6.3 to 0.2) | −0.4 (−4.4 to 3.6) | −1.2 (−5.5 to 3.2) |
|
| −1.8 (−4.1 to 0.5) | −1.5 (−4.4 to 1.4) | −4.2 (−6.7 to −1.7) | −3.4 (−6.7 to −0.2) | 2.4 (−1.0 to 5.8) | 2.0 (−2.4 to 6.4) |
|
| 4.1 (1.6 to 6.6) | 3.6 (0.4 to 6.8) | 5.0 (2.2 to 7.8)*** | 4.3 (0.7 to 7.9) | −0.9 (−4.6 to 2.8) | −0.7 (−5.5 to 4.1) |
|
| −5.6 (−7.7 to −3.6)*** | −4.2 (−6.8 to −1.6) | −2.3 (−4.5 to −0.0) | −2.1 (−5.1 to 0.8) | −3.4 (−6.4 to −0.3) | −2.1 (−6.0 to 1.8) |
P < 0.05.
P < 0.01.
P < 0.001.
Abbreviations: BSI‐18, Brief Symptom Inventory‐18; PANAS, Positive and Negative Affect Schedule; PROMIS, Patient‐Reported Outcomes Measurement Information System; SF‐36, Short Form‐36; TMS, Toronto Mindfulness Scale.
Figure 2(A) Effect of mindfulness‐based stress reduction (MBSR) on mindfulness. *Between‐group change from baseline, P < 0.05. (B) Effect of MBSR on perceived stress. *Between‐group change from baseline, P < 0.05. (C) Lack of effect of MBSR on weight. (D) Effect of MBSR on fasting glucose. **Within‐group change from baseline, P < 0.05. Data are presented as means and SE for MBSR (solid line) and health education (HE) (dashed line) groups. All analyses are by intention‐to‐treat.
Changes from baseline in metabolic measures (intent‐to‐treat analysis)
|
Mindfulness‐based stress reduction |
Health education |
Mindfulness‐based stress reduction | ||||
|---|---|---|---|---|---|---|
|
8‐week |
16‐week |
8‐week |
16‐week |
8‐week |
16‐week | |
|
| 0.4 (−0.6 to 1.3) | 0.6 (−0.5 to 1.7) | 0.1 (−0.9 to 1.2) | −0.8 (−2.1 to 0.5) | 0.2 (−1.2 to 1.6) | 1.4 (−0.3 to 3.0) |
|
| 0.1 (−0.2 to 0.5) | 0.3 (−0.1 to 0.7) | 0.1 (−0.3 to 0.5) | −0.2 (−0.6 to 0.3) | 0.1 (−0.5 to 0.6) | 0.4 (−0.2 to 1.0) |
|
| −3.2 (−6.9 to 0.5) | −0.9 (−5.6 to 3.8) | −5.0 (−9.2 to −0.8) | −1.8 (−7.1 to 3.5) | 1.8 (−3.8 to 7.4) | 0.9 (−6.2 to 7.9) |
|
| −1.6 (−3.8 to 0.7) | −0.5 (−3.1 to 2.2) | −1.7 (−4.2 to 0.8) | −0.9 (−3.8 to 2.0) | 0.1 (−3.3 to 3.5) | 0.4 (−3.5 to 4.4) |
|
| −8.9 (−16.5 to −1.3) | −9.3 (−17.1 to −1.5) | −3.2 (−12.2 to 5.8) | −3.3 (−12.1 to 5.4) | −5.7 (−17.5 to 6.0) | −6.0 (−17.6 to 5.7) |
|
| 1.0 (−5.0 to 6.9) | −1.3 (−5.7 to 3.2) | 3.9 (−3.4 to 11.3) | −2.5 (−7.7 to 2.7) | −3.0 (−12.4 to 6.5) | 1.3 (−5.6 to 8.1) |
|
| 0.2 (−0.4 to 0.9) | −0.1 (−0.6 to 0.4) | 0.4 (−0.4 to 1.3) | −0.3 (−0.9 to 0.3) | −0.2 (−1.3 to 0.9) | 0.2 (−0.6 to 1.0) |
|
| −0.0 (−0.1 to 0.1) | 0.0 (−0.1 to 0.2) | 0.1 (−0.1 to 0.2) | 0.1 (−0.1 to 0.3) | −0.1 (−0.3 to 0.1) | −0.1 (−0.3 to 0.1) |
|
| 6.1 (−1.5 to 13.8) | −1.0 (−8.2 to 6.3) | 8.0 (−1.0 to 17.0) | 4.0 (−4.7 to 12.7) | −1.9 (−13.7 to 9.9) | −5.0 (−16.3 to 6.3) |
|
| 0.2 (−1.8 to 2.1) | 0.0 (−3.3 to 3.3) | −0.1 (−2.4 to 2.2) | 1.4 (−2.5 to 5.3) | 0.3 (−2.7 to 3.3) | −1.4 (−6.5 to 3.7) |
P < 0.05.
Abbreviations: HOMA‐IR, homeostatic index of insulin resistance; HsCRP, high sensitive C‐reactive protein; LDL, low‐density lipoprotein.
Figure 3Boxplots of salivary cortisol at baseline, 8 weeks, and 16 weeks in the mindfulness‐based stress reduction (MBSR) group and the health education (HE) group.